Humanized CD37 Binding Molecules for B-Cell Depletion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for treating diseases associated with aberrant B-cell activity, such as B-cell cancers and autoimmune diseases, face limitations including relapse, toxic side effects, and inadequate efficacy due to the large size of antibodies like rituximab, which limits diffusion into lymphoid tissues and causes infusion reactions.
Innovation Solution
The use of CD37-specific binding molecules, either alone or in combination with CD20-specific binding molecules, to reduce B-cell populations, utilizing humanized constructs like TRU-016 for enhanced efficacy and specificity, thereby improving treatment outcomes for diseases characterized by aberrant B-cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large antibodies like rituximab are used for B-cell depletion, then B-cell reduction is achieved, but diffusion into lymphoid tissues is limited and infusion reactions occur
Solution Approach 1:
The patent segments the large antibody molecule into smaller binding molecules (such as antibody fragments, single-chain variable fragments, or small modular immunopharmaceuticals) that retain B-cell targeting capability but possess improved tissue penetration and reduced immunogenicity, thereby resolving the contradiction between depletion efficacy and harmful side effects
Solution Approach 2:
The patent changes the molecular size parameter of the binding agent from large intact antibodies to smaller fragments or engineered molecules, which improves diffusion into lymphoid tissues and reduces infusion reactions while maintaining B-cell depletion capability
2Reliability
If CD20-specific binding molecules are used, then B-cell depletion is achieved, but relapse occurs due to inadequate efficacy
Solution Approach 1:
The patent employs composite binding molecules that combine CD20-targeting domains with CD37-targeting domains in a single molecular construct, creating a dual-specific binding molecule that simultaneously engages both antigens on B-cells, thereby enhancing depletion efficacy and preventing relapse while maintaining targeted action
3Productivity
If combination therapy with CD37-specific and CD20-specific binding molecules is used, then synergistic B-cell reduction is achieved, but treatment complexity increases
Solution Approach 1:
The patent merges CD37-specific and CD20-specific binding domains into a single dual-specific binding molecule, which can be administered as a single therapeutic agent rather than requiring separate administrations of multiple drugs, thereby achieving synergistic B-cell depletion while simplifying the treatment regimen and reducing administrative complexity
Data Source
AI summary
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.